摘要：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整

编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。（注：因官网未公布详细作者单位，如有遗漏或错误，欢迎留言指正。）

Poster Session 2

日期：12月11日

时间：5:30～7:00 p.m.

地点：Halls 2-3

P2-01-23: A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC

一个包含140个基因的机器学习分类器预测了2500例三阴性乳腺癌（TNBC）患者的生存率以及对化疗和免疫治疗的反应

报告作者：Xixuan Zhu

P2-02-09: Novel Intramolecular BRCT Domain Interaction with ECT2 C-terminal Intramolecular Interaction Domain Regulates GEF Activity and Tumorigenesis

新型分子内BRCT结构域与ECT2 C端分子内相互作用结构域相互作用调节GEF活性和肿瘤发生

报告作者：Jinyu Lu

P2-02-11: Unveiling the subtype-specific role of PTPRK in triplenegative breast cancer: Implications for targeted therapies

揭示PTPRK在三阴性乳腺癌中的亚型特异性作用：对靶向治疗的启示

报告作者：Xiangyi Liu

P2-02-14: C1QL1 inhibits breast cancer through HSP90α/VCPERS/UPR axis

C1QL1通过HSP90α/VCPERS/UPR轴抑制乳腺癌

报告作者：Ningning Zhang

P2-02-15: Engineered macrophages secreting TRAIL achieve immunotherapy for triple-negative breast cancer by inhibiting the Wnt/β-catenin signaling pathway

分泌TRAIL的巨噬细胞通过抑制Wnt/β-catenin信号通路实现对三阴性乳腺癌的免疫治疗

报告作者：Chuangui Song

P2-02-19: Virtual Multiplex Immunofluorescence Identifies Lymphocyte Subsets Predictive of Response to Neoadjuvant Therapy

虚拟多重免疫荧光识别淋巴细胞亚群预测对新辅助治疗的应答

报告作者：Anran Li

P2-02-20: Prediction of Axillary Lymph Node Metastasis in Breast Cancer using Intraoperative Fluorescence Multi-modal Imaging

术中荧光多模态成像对乳腺癌腋窝淋巴结转移的预测

报告作者：He Sun

P2-03-17: Targeting NR2F2 overcomes multiple forms of endocrine resistance

靶向NR2F2可克服多种形式的内分泌耐药

报告作者：Yanyan Cai

P2-03-18: Lymph node metastasis of breast cancer: subclonal selection for high lipid metabolism from the primary tumor

乳腺癌淋巴结转移：原发肿瘤高脂代谢的亚克隆选择

报告作者：Yue Zhou

P2-04-02: TRIB3 regulates lipophagy and drives the metastasis of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway

TRIB3通过激活PI3K/AKT/mTOR通路调控脂噬，进而驱动三阴性乳腺癌的转移

报告作者：zirong jiang

P2-04-04: Integrated stress response-upregulated mitochondrial SLC1A5var enhances glucose dependency of human breast cancer cells

整合应激反应上调的线粒体SLC1A5增强了人乳腺癌细胞的葡萄糖依赖

报告作者：Sheng-Fan Wan

P2-04-07: Dual function of PRAK in TP53-associated breast cancer metastasis

PRAK在tp53相关乳腺癌转移中的双重功能

报告作者：Jingjing Liu

P2-04-08: Functions of KLF5 in the cell cycle and breast cancer cell Proliferation

KLF5在细胞周期和乳腺癌细胞增殖中的作用

报告作者：Xiaoyun Mao

P2-04-09: A Novel Role of IP6K2 in Regulating Host Cell Death through p21-mediated cell cycle arrest during HSV-1 oncolytic virus Therapy

在HSV-1溶瘤病毒治疗过程中，IP6K2通过p21介导的细胞周期阻滞调控宿主细胞死亡的新作用

报告作者：Zhijian Huang

P2-04-10: ARL3 Promotes Hormone Receptor Positive Breast Cancer Progression and Tamoxifen Resistance through ERα Stablization

ARL3通过ERα稳定促进激素受体阳性乳腺癌进展和他莫昔芬耐药

报告作者：Han Li

P2-04-11: Selective Pre-clinical Targeting of CD44+ ADAR1+ Triple Negative Breast Cancer

针对CD44+ ADAR1+三阴性乳腺癌的选择性临床前靶向治疗

报告作者：Wenxue Ma

P2-04-12: JAM A expression and its clinical/prognostic value in breast cancer

JAM A在乳腺癌中的表达及其临床预后价值

报告作者：Yufei Lou

P2-04-19: Identification and Validation of Novel Necroptosis-Related lncRNAs for Prognostic Prediction in Breast Cancer

乳腺癌中新型坏死性凋亡相关长链非编码RNA的鉴定及其预后预测验证

P2-04-25: Different Pyroptosis Phenotype within Breast Cancer Possess Distinctive Prognosis and Tumor Immune Microenvironment

乳腺癌中不同的细胞焦亡表型具有不同的预后和肿瘤免疫微环境

报告作者：Ye Hong

P2-04-26: Predicting the prognosis and immunotherapeutic response of triplenegative breast cancer by constructing a prognostic model based on CD8T cellrelated immune genes

基于CD8+T细胞相关免疫基因构建预后模型预测三阴性乳腺癌的预后及免疫治疗反应

P2-04-29: Predictive model of prognosis index for invasive micropapillary carcinoma of the breast based on machine learning: A SEER population-based study

基于机器学习的乳腺浸润性微乳头状癌预后指数预测模型：一项基于SEER人群的研究

P2-05-10: Depression and anxiety in patients with breast cancer receiving radiotherapy: A prospective longitudinal study

接受放疗的乳腺癌患者的抑郁和焦虑情况：一项前瞻性纵向研究

报告作者：Shi-Jia Wang

P2-05-11: A prospective cohort study of real-world patientreported outcomes in HER2-positive early breast cancer patients receiving (neo) adjuvant anti-HER2 based therapy: the preliminary results at 2-cycle treatment

一项关于接受（新）辅助抗HER2治疗方案的HER2阳性早期乳腺癌患者真实世界患者报告结局的前瞻性队列研究：2周期治疗后的初步结果

报告作者：Ke-Da YU

P2-05-19: An ICG-labeled Novel Trop2 Targeting Peptide for In Vivo and Ex Vivo NIR-II Fluorescence Imaging-guided Breast Cancer Precise Surgery

一种ICG标记的新型Trop2靶向肽，用于体内和离体NIR-II荧光成像引导的乳腺癌精准手术

报告作者：Kangliang Lou

P2-05-25: Comparative Study of Droplet-digital PCR and Ultrasensitive NGS Assay for ctDNA Profiling in Breast Cancer

乳腺癌ctDNA特征分析：液滴数字PCR与超灵敏NGS检测的比较研究

报告作者：Binggang Xiang

P2-05-27: Revealing prognostic subtypes and related model of early-stage TNBC

揭示早期三阴性乳腺癌的预后亚型及相关模型

报告作者：Peifen FU

P2-06-01: CBP/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in TNBC

CBP/P300溴结构域抑制可减少三阴性乳腺癌中的中性粒细胞积聚并激活抗肿瘤免疫

报告作者：Xueying Yuan

P2-06-12: MGAT1-Mediated Glycosylation Orchestrates Immune Checkpoints and Antitumor Immunity

MGAT1介导的糖基化调控免疫检查点和抗肿瘤免疫

报告作者：Junlong Chi

P2-06-14: Calcium-Sensing Receptor Agonist Enhanced AntiTumor Activity of Adoptive NK Cell Therapy in Triple-Negative Breast Cancer

钙敏感受体激动剂增强三阴性乳腺癌中过继性NK细胞治疗的抗肿瘤活性

报告作者：Yu Shi

P2-06-23: Using a Machine Learning Model for Prediction of Palbociclib Response in a Single Institution, Real-World Analysis of Patients with ER+ HER2- Advanced Breast Cancer

应用机器学习模型预测单中心真实世界中ER+/HER2-晚期乳腺癌患者对哌柏西利治疗的反应

报告作者：Xiaojie Zhang

P2-07-03: Noninvasive imaging of breast cancer and metastasis using TROP2-targeting radiotracer 68Ga-TTP

利用TROP2靶向放射性示踪剂68Ga-TTP对乳腺癌及其转移进行无创成像

报告作者：Yifei Pei

P2-07-14: Head-to-head comparison of the dual-targeting tracer [68Ga]Ga-RM26-RGD and [18F]FDG for PET imaging of breast cancer

双靶点示踪剂[68Ga]Ga-RM26-RGD与[18F]FDG在乳腺癌PET成像中的头对头比较

报告作者：Qingyao Shang

P2-07-27: Long-term administration of endocrine therapy on the gut microbiota of breast cancer patients between disease-free and recurrence

长期内分泌治疗对乳腺癌患者无病生存期与复发期间肠道微生物群的影响

报告作者：Ming-Feng Hou

P2-08-13: Effectiveness of Combined Neoadjuvant Pembrolizumab and Chemotherapy in Early Triple-Negative Breast Cancer: Real-World Evidence from Multiple Centers in Asia

早期三阴性乳腺癌中帕博利珠单抗联合新辅助化疗的疗效：来自亚洲多家中心的真实世界证据

报告作者：Yu-Ting Lin

P2-09-08: Correlating Breast Density with FDG-avidity on PET Imaging

乳腺密度与PET成像中FDG摄取程度的相关性

报告作者：YiLi Zhao

P2-09-11: Improved Prediction of Axillary Lymph Node Metastasis in Early-Stage Breast Cancer Using Deep Learning on Routine Mammography

利用深度学习常规乳腺钼靶检查改善早期乳腺癌腋窝淋巴结转移的预测

报告作者：Daqu Zhang

P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/ HER2- advanced breast cancer: the Linux trial

基于多组学相似性网络融合（SNF）亚型的精准医疗在CDK4/6抑制剂治疗失败的HR+/HER2-晚期乳腺癌中的应用：Linux试验

报告作者：Lei Fan

P2-09-28: Dalpiciclib plus endocrine therapy for visceral crisis in advanced breast cancer: a multicenter, prospective, external controlled phase 2 study

达尔西利联合内分泌治疗内脏危象的晚期乳腺癌：一项多中心、前瞻性、外部对照的II期研究

报告作者：Hongnan Mo

P2-10-01: Real-world Experience with CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic and Recurrent Breast Cancer in Asian Population

CDK4/6抑制剂在亚洲人群激素受体阳性转移性和复发性乳腺癌中的真实世界应用经验

报告作者：Bo-Fang Chen

P2-10-08: The Impact of Time-to-Surgery (TTS) for Breast Cancer Prognosis After Neoadjuvant Chemotherapy

新辅助化疗后手术时间（TTS）对乳腺癌预后的影响

报告作者：Xin Wang

P2-10-13: The Real World Practice of Prospectively Breast Cancer Screening Program for High Polygenic Risk Score Population in Taiwan

台湾针对高多基因风险评分人群的前瞻性乳腺癌筛查计划的实际应用情况

报告作者：Yu-Wen Weng

P2-10-16: A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment (YCT)

瑜伽治疗化疗所致周围神经病变的随机III期临床试验（YCT）

报告作者：Ting Bao

P2-11-01: Comprehensive spatially resolved single-cell analysis of immunotypes in triple-negative breast cancer revealed the central role of intratumoral MHC class II expressions

三阴性乳腺癌中免疫类型的全面空间分辨单细胞分析揭示了肿瘤内MHC II类表达的核心作用

报告作者：Yi Liu

P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial

局部晚期免疫调节性三阴性乳腺癌患者中新辅助化疗联合卡瑞利珠单抗与单纯化疗的比较：一项前瞻性、随机、开放性II期临床试验

报告作者：Li Chen

P2-11-13: Retrospective validation of digital twin-based prediction of personalized triple negative breast cancer response to neoadjuvant therapy regimens

基于数字孪生的个性化三阴性乳腺癌新辅助治疗方案反应预测的回顾性验证

报告作者：Chengyue Wu

P2-12-22: A multicenter, single-arm, phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer.

口服CDK4/6抑制剂darciclib联合内分泌治疗辅助治疗激素受体阳性、HER2阴性女性乳腺癌的多中心、单臂、II期临床试验

报告作者：Jie Ouyang

来源：肿瘤瞭望